viewC4X Discovery Holdings PLC

C4X Discovery - Clive Dix appointed to the UK Vaccine Taskforce

RNS Number : 0418P
C4X Discovery Holdings PLC
05 June 2020

C4X Discovery Holdings plc


("C4XD", "C4X Discovery" or the "Company")


Clive Dix appointed to the UK Vaccine Taskforce


Government's taskforce to lead UK efforts to deliver a COVID-19 vaccine


5 June 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, is pleased to confirm that Clive Dix, Chief Executive Officer of C4XD has been appointed a member and Deputy Chair of the Steering Board of the UK Vaccine Taskforce, the group set up by the Government's Chief Scientific Adviser, Deputy Chief Medical Officer, Business Secretary and Health Secretary to lead UK efforts to find and manufacture a COVID-19 vaccine. 


Clive remains committed to delivering C4XD's strategy and this appointment will not impact his day-to-day role as CEO.


Eva-Lotta Allan, Chairman of C4XD, commented:

"We are very proud that Clive has been appointed to this important and prestigious taskforce.  COVID-19 has had such a devastating impact not only in the UK, but across the world.  The development of a vaccine is vital to saving lives and enabling everyone to get back to normality.  The taskforce has been assembled to bring together the brightest minds in the scientific industry to deliver a COVID-19 vaccine that will be effective and accessible.  Clive's rich and diverse experience, both as a scientist and from managing pharmaceutical companies, means he understands what is required to bring a product like this to market.  This will be invaluable to the taskforce as it works quickly to find a solution to the COVID-19 pandemic." 


- Ends -




C4X Discovery Holdings

Mo Noonan, Communications

+44 (0)787 6444977

Panmure Gordon (UK) Limited (NOMAD and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

+44 (0)20 7886 2500

James Stearns (Corporate Broking)

C4X Discovery Media - Consilium Strategic Communications

Mary-Jane Elliott, Chris Gardner, Matthew Neal

+44 (0)203 709 5700



Notes to Editors:


About the UK Vaccine Taskforce

The Taskforce is supporting efforts to develop a COVID-19 vaccine as soon as possible by providing industry and research institutions with the resources and support needed. This includes working with regulators and scaling up manufacturing, so that when a vaccine is identified, it can be produced quickly and at scale.


The Bioindustry Association is working closely with the Taskforce, bringing together a whole range of businesses keen to use their expertise to mass-produce vaccines, as soon as one is ready.


About C4X Discovery

C4X Discovery (C4XD) aims to create the world's most productive Drug Discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company's business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m.


C4XD has a state-of-the-art suite of proprietary technologies across the Drug Discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD's commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.


For additional information please go to: www.c4xdiscovery.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: C4X Discovery Holdings PLC

Price: 17.5

Market: AIM
Market Cap: £20.86 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


C4X Discovery CEO welcomes start of Indivior trial and outlines new...

C4X Discovery PLC's (LON:C4XD) Chief Executive Clive Dix speaks to Proactive London about the start of clinical trials of a treatment for opioid dependence. The phase I, single ascending dose trial of the company’s Orexin-1 antagonist, C4X_3256, should be completed by the end of the year. Dix...

on 25/8/20

4 min read